Form 4: Dynavax Technologies SVP and CMO Reports Stock Transactions
SEC Form 4 Filing
Robert Janssen, SVP and CMO of Dynavax Technologies, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On February 10, 2025, Robert Janssen, SVP and CMO of Dynavax Technologies, reported transactions involving Dynavax common stock.
- These transactions included the vesting of 4,333 restricted stock units (RSUs) and the withholding of 1,781 shares to cover tax obligations.
- Following these transactions, Janssen directly owns 61,236 shares of Dynavax common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the biotechnology industry. It provides transparency into the executive's holdings and transactions in the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for corporate insiders in publicly traded companies, ensuring transparency and compliance with SEC regulations.
- Similar filings are routinely made by executives at comparable biotechnology companies like Moderna (MRNA) and BioNTech (BNTX) when they engage in stock transactions.
Key Dates
| Date | Description |
|---|---|
| February 10, 2022 | Initial vesting date of the Restricted Stock Units (RSUs) over three years with 1/3 vesting on each annual anniversary. |
| February 10, 2025 | Date of transaction: vesting of RSUs and tax withholding. |
| February 12, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.